US patent for Acusphere contrast agents
This article was originally published in Clinica
Executive Summary
Acusphere has received a US patent relating to its gas-filled microspheres for use in enhancing ultrasound contrast agents. The patent covers the company's method of making the high-porosity (hollow) microspheres which have the low porosity outer shell from synthetic polymers. While an increased internal porosity allows the microspheres to hold more gas, thus improving the contrast agent's effectiveness, a low porosity of the external shell prevents the gas from leaking out of the micro-particle, said the company of Cambridge, Massachusetts. Acusphere has also started a US Phase I clinical trial to test its lead contrast agent, AI-700, as a means of assessing myocardial perfusion.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.